Supplementary Information

eMethods. Supplementary Methods

eFigure 1. Forest Plots of PTSD-associated CpGs in each cohort.

eFigure 2. Manhattan plots of the stratified analyses.

eFigure 3. Forest Plots of CpGs associated with PTSD in the stratified analysis for females.

eFigure 4. Forest Plots of CpGs associated with PTSD in the stratified analysis for males.

eFigure 5. Forest Plots of CpGs associated with PTSD in the stratified analysis for European ancestry.

eFigure 6. Forest Plots of CpGs associated with PTSD in the stratified analysis for African ancestry.

eFigure 7. Forest Plots of CpGs associated with PTSD in the stratified analysis for civilian trauma.

eFigure 8. Forest Plots of CpGs associated with PTSD in the stratified analysis for military trauma.

eTable 1. PTSD-associated CpGs from the primary analysis in the sensitivity analysis adjusted for smoking score.

eTable 2. PTSD-associated CpGs from the primary analysis in the stratified analysis for sex, ancestry, and trauma type

eTable 3. Gene Ontology Enrichment results in females.

eTable 4. Correlation values of methylation between blood and brain regions from Blood Brain DNA Methylation Comparison Tool.

eTable 5. Results of PTSD-associated CpGs from blood in the brain.

eTable 6. Results of PTSD-associated CpGs from blood in neuronal nuclei.

eTable 7. Results of PTSD-associated CpGs from blood in fibroblasts.

eTable 8. DNA methylation and cis-gene expression (RNAseq) correlations.

eTable 9. Significant SNPs from cis-meQTL analysis and their association with PTSD.

eTable 10. Genetic associations of the identified PTSD-associated genes from gene-based tests. References.

eMethods

Cohort Information

Biomarkers, social, and affective predictors of suicidal thoughts and behaviors in adolescents (*BEAR*). The BEAR study, described in detail elsewhere¹, involved a sample of 194 adolescents (ages 13-18) who had been hospitalized for suicidal thoughts/behaviors. Blood collection and clinical interview procedures were completed during hospitalization. Trauma exposure and symptoms of posttraumatic stress disorder (PTSD) were assessed via clinical interview with gold standard measures, specifically the Life Events Checklist for DSM-5² and the Clinician Administered PTSD Scale for Children and Adolescents for DSM-5³. If participants endorsed multiple traumatic experiences, participants were asked to focus on current symptoms related to the most upsetting event. All participants were consented to the present research and procedures were approved by the Lifespan Hospitals IRB.

Detroit Neighborhood Health Study (DNHS). As detailed in a previous study⁴, participants (n=1,547 at the baseline wave) were assessed for PTSD symptoms using the PTSD checklist (PCL-C), a 17-item self-report measure of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) symptoms, and additional questions about duration, timing, and impairment or disability due to the symptoms⁵. Participants were initially asked to identify Potentially Traumatic Events that they experienced in the past from a list of 19 events. PTSD symptoms were then assessed by referencing two traumatic events that the respondent may have experienced: one that the participant regarded as the worst and one randomly selected event from the remaining PTEs a respondent may have experienced. Respondents were considered affected by lifetime PTSD if all six DSM-IV criteria were met in reference to either the worst or the random event. Current PTSD was then identified based on whether participants endorsed experiencing symptoms within the last month. The DNHS was approved by the institutional review board at the University of Michigan and University of North Carolina at Chapel Hill.

Drakenstein Child Health Study (DCHS). The Drakenstein Child Health Study (DCHS)⁶, is a population based birth cohort, with participants initially recruited in a peri-urban area in South Africa. Pregnant women were enrolled from March 2012 to March 2015. Pregnant women who were 18 years or older, between 20-28 weeks gestation, and residing in the area were enrolled from 2 public health clinics. Study visits were synchronized with health care and immunization visits. During the first two years of the study, additional study visits occurred at 6, 12 and 24 months, and mother-infant pairs could also participate in intensive biweekly follow-up during the first year. Mother-child pairs were followed from birth through childhood, collecting longitudinal measurements of risk factors encompassing environmental, nutritional, immunological, genetic, infectious, and maternal factors. Maternal smoking or passive smoke exposure was self-reported. A composite measure of socioeconomic status (SES), encompassing current employment, education, household income and an asset index, was based on previous work in the South African Stress and Health Study. Maternal mental health measures included assessments of PTSD, depression, psychological distress, and intimate partner violence (IPV)

both antenatally and postnatally. For the purpose of this study, PTSD was assessed using The Mini International Neuropsychiatric Interview (MINI)^{7,8}.

Grady Trauma Project (GTP). GTP research participants were approached in the waiting rooms of the primary care clinic or obstetrical-gynecological clinic of a large, urban, public hospital in Atlanta, GA while either waiting for their medical appointments or while waiting with others who were scheduled for medical appointments⁹. Subjects willing to participate provided written informed consent and participated in a verbal interview and blood draw. Current and lifetime PTSD diagnosis was assessed by clinical psychologists using the Clinician-Administered PTSD Scale for DSM IV (CAPS-4)^{10,11} or the modified PTSD Symptomatic Scale (PSS)¹². For this study, cases were specified as having current PTSD, and controls had no current or lifetime history of the disorder. Demographic variables including age, sex and race were assessed through self-report. The Institutional Review Boards of Emory University School of Medicine and the Research Oversight Committee of Grady Memorial Hospital approved this study.

Northern Illinois University Trauma Study (NIU). Data were collected from women who completed multiple waves of a federally-funded longitudinal study (NIH 5R21MH085436-02) approved by the Northern Illinois University (NIU) Institutional Review Board. Between August 2006 and February 14, 2008, female students enrolled in an Introductory Psychology course received partial course credit for completing an initial assessment for a longitudinal study. Participants provided written informed consent and completed computerized surveys in individual face-to-face sessions. Following the NIU campus shooting on February 14th, 2008 (the fourth deadliest university shooting in U.S, history at that time), the NIU Trauma Study was launched to examine risk and protective factors following the event. Women previously enrolled in the ongoing longitudinal investigation were recruited to participate in a multi-wave longitudinal study examining post-shooting adjustment. Seventeen days following the shooting, eligible participants (n = 812 of the 885 participants who consented to follow-up contact and were current NIU students) were invited to participate in the post-shooting adjustment study via e-mail. Of these participants, 691 (85.10%) completed the initial post-shooting assessment and were recruited for subsequent post-shooting assessments over the next 30 months. Between October 2012 and February 2015, these 691participants were recruited via e-mail, phone call, and mail contact to participate in a federally-funded study (NIH 1R15MH099521-01) including a fear-potentiated startle experimental session. Of those eligible, 131 (18.96%) completed the experimental session and provided blood and saliva samples. Written informed consent was obtained for the experimental session and samples. The Institutional Review Board of Northern Illinois University approved this study. Current PTSD diagnosis at the first postshooting assessment was assessed by self-report on the Distressing Events Questionnaire (DEQ)¹³ and cases were specified as having a score greater or equal to 18 on the DEQ and controls had a score of 17 or lower. Demographic variables including age, race, and ethnicity were assessed through self-report.

Shared Roots. SHRS or "Understanding the SHARED ROOTS of Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular Disease" was a matched case-control study examining the factors that contribute to the comorbidity of metabolic syndrome and

neuropsychiatric disorders¹⁴. Controls were trauma-exposed. Potentially traumatic events were identified using the Life Events Checklist for DSM-5 (LEC-5)². The CAPS-5¹⁵ was administered by clinicians to assess PTSD over the prior month. The CAPS-5 and the PTSD Checklist for DSM-5 (PCL-5)¹⁶ were both administered to assess PTSD symptom severity. Lifetime diagnosis of PTSD was not assessed for in this study. Childhood trauma was assessed using the Childhood Trauma Questionnaire (CTQ)¹⁷. Demographic variables including age, sex and race were assessed through self-report. The Institutional Review Board of Stellenbosch University approved this study (HREC: N13/08/115).

Advancing Understanding of RecOvery after traumA (AURORA). The AURORA study is a large multi-ancestry cohort study of women and men presenting to the ED within 72 hours after exposure to psychological trauma¹⁸. Inclusion and exclusion criteria for AURORA participants were as follows. Patients aged 18–75 years who presented to the ED within 72 hours of trauma exposure at participating emergency department (ED) sites were screened for study eligibility. Trauma exposures automatically qualifying for study enrollment were motor vehicle collision, physical assault, sexual assault, fall greater than 10 feet, or mass casualty incidents. Other trauma exposures also gualified if: (1) the individual responded to a screener guestion that they experienced the exposure as involving actual or threatened serious injury, sexual violence, or death, either by direct exposure, witnessing, or learning about it; and (2) the research assistant agreed that the exposure was a plausible qualifying event. Exclusion criteria included administration of general anesthesia, long bone fractures, laceration with significant hemorrhage, solid organ injury > American Association for the Surgery of Trauma Grade 1, not alert and oriented at the time of enrollment, not fluent in written or spoken English, visual or auditory impairment precluding completion of web-based neurocognitive evaluations and/or telephone follow-ups, self-inflicted or occupational injury, prisoners, individuals pregnant or breastfeeding, individuals reporting ongoing domestic violence, and individuals taking > 20 mg morphine or equivalent per day. Eligible patients also needed to have an iOS or Androidcompatible smartphone with internet access and an email address that they check regularly. Probable PTSD diagnosis at 6 months was defined using the PTSD Checklist for DSM-5 (PCL-5) a 20-item self-report scale that uses a 0-4 response format asking how much the participant was "bothered by" each PTSD symptom (0-4 scale) in the past 30 days – and a previously established PCL-5 score threshold of $\geq 31^{19-21}$. The present study is focused on a subset of the AURORA cohort with available phenotypic, DNA methylation, and RNA sequencing data at the 6-month follow-up after trauma exposure (n=206, 57 (27.675%) current probable PTSD, 154 (74.76%) women, 67 (32.52%) White, 131 (63.59%) Black. With a mean age of 39.55 (SD=14.34)).

Human Heredity and Health in Africa, Rwanda (H3A_Rwanda). Data from the H3A_Rwanda cohort were obtained from a subset of participants in a previously published pilot study (n=30)^{22,23} and from newly recruited participants via support from the H3Africa Consortium (n=40)²⁴. All study participants were women of Tutsi ethnicity who were pregnant during the genocide. The pilot study participants were recruited via genocide survivor's association known as Association of Genocide Widows Agahozo (AVEGA) and PTSD was assessed by a trained psychologist according to DSM-IV criteria using the PCL-17²⁵, translated into Kinyarwanda. The

H3Africa-affiliated participants were recruited in collaboration with local NGOs who work closely with the target population, mainly the AVEGA and Compassion International Rwanda, a religiously inspired organization that helps children in the community. The data collection was conducted via 2019-2023 and PTSD was assessed via a self-administered questionnaire using the PCL-5 including criterion A²⁶, translated into Kinyarwanda, according to DSM 5 criteria. This tool was validated by Harvard Trauma Questionnaires (HTQ). All subjects provided written informed consent and participated in a blood draw. Participants in the pilot study were recruited prior to those in the H3Africa-related study. Two participants overlapped between studies, such that among the 73 samples included in the current meta-analysis there were 71 unique participants. One of the two repeat participants was a control at both time points, whereas the other participant was a PTSD case at one time point and a control at another. The two studies were approved by the Institutional Review Board of the University Teaching Hospital of Kigali (pilot study- Ref EC/CHUK/025/11) and The Institutional Review Board of the College of Medicine and Health Sciences at the University of Rwanda (No.370/CMHS/IRB/2020).

World Trade Center Responders (WTC). As described by Bromet and colleagues^{27,28}, responders enrolled in the Stony Brook University/Long Island WTC Health Program were administered the SCID PTSD module modified to assess PTSD in relation to WTC exposures. The sample providing blood samples for the epigenetics assays was restricted to men (the vast majority of the responders) and oversampled for posttraumatic stress disorder (PTSD)²⁹. The Committees on Research Involving Human Subjects at Stony Brook University approved the study.

Gallipoli Medical Research Foundation Queensland University of Technology (GMRFQUT). The GMRF-QUT cohort comprised of a large cohort of veterans who have been or were currently being treated for PTSD at the Keith Payne Unit within the Greenslopes Private Hospital in Queensland, Australia³⁰. Subjects willing to participate provided written informed consent and participated in a verbal interview with a clinician and blood draw. The Clinician Administered PTSD Scale for DSM 5 (CAPS-5)^{10,11} was used to assess PTSD over the prior 2 weeks and lifetime by clinical psychologists. Respondents were considered to have a current diagnosis if CAPS-5 criteria were met. For this study, cases were specified as having current PTSD, and controls had no current or lifetime history of the disorder. Demographic variables including age, sex and race were assessed through self-report questionnaires. Ethics approval for the project was obtained from the Human Research Ethics Committee of the Queensland University of Technology and Greenslopes Private Hospital. This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

Marine Resiliency Study (MRS). In the MRS^{31,32}, PTSD was diagnosed up to 3 times, once before deployment and 3 and/or 6 month post deployment. Post-traumatic stress (PTS) symptoms were assessed using a structured diagnostic interview, the Clinician Administered PTSD Scale (CAPS), and PTSD diagnosis followed the DSM-IV criteria for partial and full PTSD and a minimum CAPS score of 40. None of the participants in the EWAS had PTSD at pre-deployment (CAPS scores \leq 25). Samples of PTSD cases were selected from the 3- or 6-months post-deployment visits depending on which visit had the highest CAPS score. Combat-exposed controls with low to no PTSD-symptoms were selected from post-deployment visits, matching

for age, ancestry, and time of post-deployment visit. The study was approved by the institutional review boards of the University of California San Diego, VA San Diego Research Service, and Naval Health Research Center. All participants provided informed consent.

Prospective Research in Stress-related Military Operations (PRISMO). PRISMO is a large prospective study of well-characterized Dutch military soldiers scheduled for a deployment of at least four months to Afghanistan with longitudinal follow-up^{33,34}. Current PTSD symptoms were assessed using the Self-Report Inventory for PTSD (SRIP)³⁵, and blood samples were collected approximately 1 month before and at both 1 and 6 months after deployment. Traumatic stress exposure during deployment to Afghanistan was assessed with a 19-item deployment experiences checklist, as previously reported³⁶. PTSD cases were selected for this DNA methylation study from the 1- or 6-months post-deployment visits, depending on which visit had the highest SRIP score. All controls were combat-exposed and had low PTSD symptoms³⁷. The study was approved by the Institutional Review Board of the University Medical Center Utrecht (Utrecht, the Netherlands), and was conducted in accordance with the Declaration of Helsinki. Written consent was obtained from all participants.

The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). Army STARRS is a multicomponent prospective study of risk-resilience factors for suicidality and its psychopathological correlates among US Army personnel³⁸. Participants completed a computerized version of the Composite International Diagnostic Interview screening scales (CIDI-SC) and a 6-item screening version of the PTSD Checklist (PCL-6) for DSM-IV ~6 weeks before deployment to Afghanistan, and the PCL for DSM-IV at 1-, 2-, and 6-months postdeployment. Trauma exposure was assessed from answers pertaining to childhood, adulthood civilian, and military traumatic events. PTSD diagnosis was assigned using multiple imputation methods that relied on PCL and CIDI-SC data³⁹. Whole blood for methylation assays was collected approximately 6 weeks before deployment and 1-month post-deployment. None of the subjects were diagnosed with PTSD prior to deployment. PTSD cases were selected based on their PTSD diagnosis at 6 months post-deployment. Controls were subjects without PTSD, matched on age, deployment stress, and childhood adversity. The recruitment, consent, human subject, and data protection procedures were approved by the Human Subjects Committees of the Uniformed Services University of the Health Sciences for the Henry M. Jackson Foundation (the primary grantee), the Institute for Social Research at the University of Michigan (the organization collecting the data), and all other collaborating organizations. All subjects provided informed consent.

PROlonGed ExpoSure and Sertraline Trial (PROGrESS). The participants included in the study were part of a larger study of the PROlonGed ExpoSure and Sertraline Trial (PROGrESS), a foursite [VA Ann Arbor Healthcare System (VAAAHS), Ralph H. Johnson VA Medical Center (CHSVAMC), Massachusetts General Hospital (MGH), and VA San Diego Healthcare System (VASDHCS) randomized-controlled trial (RCT; N = 223), designed to examine: 1) the comparative effectiveness of Prolonged Exposure plus placebo (PE/PLB), Sertraline plus Enhanced Medication Management (SERT/EMM), or combined treatment (PE/SERT) on PTSD, and 2) neurobiological predictors and potential biomarkers of treatment response including hypothalamic-pituitary-adrenal axis (HPA), brain, and genetic/genomic biomarkers^{40,41}. PROGrESS was approved by the institutional review boards at VHAAAHS, the University of Michigan, VASDHCS, CHSVAMC, MGH and the Department of Defense Human Research Protection Office (HRPO). Participants provided written informed consent before enrollment. Participants and clinicians were blinded to pill condition through week 24, and independent evaluators were blinded to treatment assignments for the duration of the study. The PROGrESS study methods were published in detail^{40,41}. Briefly, inclusion criteria were service members or veterans of the Iraq or Afghanistan wars with combat-related PTSD and significant impairment (Clinicians-Administered PTSD Scale for DSM-IV [CAPS-IV] [26] score \geq 50) of at least 3 months' duration. Exclusion criteria included factors related to safety and appropriateness of psychotherapy and sertraline treatment^{40,41}. For this study, PTSD cases and controls were selected from the pre-treatment visit.

Boston VA National Center for PTSD / Translational Research Center for TBI and Stress Disorders (NCPTSD/TRACTS). These analyses were performed using two cohorts comprising samples from three studies collected at the Boston VA Healthcare System. The VA Boston National Center for PTSD (NCPTSD) cohort includes subjects from two studies, the NCPTSD study (Miller PI) 42 , and the PTSD & Accelerated Aging study (Wolf PI, Wolf et al., under review⁴³). The NCPTSD study included trauma-exposed veterans and a subset of their trauma-exposed intimate partners. The PTSD & Accelerated Aging study included Veterans who screened positive for PTSD and who were subsequently evaluated comprehensively. The Translational Research Center for TBI and Stress Disorders (TRACTS)-study cohort (Milberg and Fortier PIs)⁴⁴ includes post-9/11 Veterans recruited for a study of TBI. For all three studies, PTSD diagnostic status was determined based on the Clinician-Administered PTSD Scale (CAPS) for DSM-IV¹⁰ or DSM-5⁴⁵ and the Traumatic Life Events Questionnaire (TLEQ)⁴⁶ was used to assess adult and childhood trauma. The NCPTSD and TRACTS cohort DNAm data were jointly cleaned and analyzed together. For both cohorts, DNAm was measured at the Central Arkansas Veterans Healthcare System Pharmacogenomics Analysis Laboratory (PAL) using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer's protocols. Data cleaning and analyses were performed using the PGC-PTSD Workgroup quality control/analysis pipeline (https://github.com/PGC-PTSD-EWAS/EPIC_QC).

Injury and Traumatic Stress (INTRuST). Patients and healthy controls were recruited from INTRuST clinical trials (with DNA collected prior to treatment) or specifically to contribute to the INTRuST biorepository. Patients were diagnosed with PTSD using study-specific measures which could have included either the CAPS-IV or CAPS-5, the MINI, or self-report using the PCL. Healthy controls were determined to be free of major psychiatric diagnoses, including PTSD, using the MINI or a comparable clinical interview. The Human Research Protection Program (HRPP) at UCSD approved this study, as did all the IRBs at participating sites.

Mid-Atlantic Mental Illness Research Education and Clinical Center PTSD Study (VA-M-AA & VA-M-EA). As described previously⁴⁷, PTSD was diagnosed using the Structured Clinical Interview for DSM-IV Disorders (SCID) administered by trained interviewers. In accordance with the DSM-IV, PTSD consists of three symptom clusters. These include re-experiencing symptoms (B symptoms), avoidance and numbing symptoms (C symptoms) and hyperarousal symptoms (C

symptoms). Total PTSD symptoms and symptom clusters (B, C, or D) were measured using the Davidson Trauma Scale for all veterans including individuals with current PTSD diagnosis and controls. The research was reviewed and approved by the Institutional Review Boards at the Salisbury VA, Hampton VA, Durham VA and Duke University Medical Centers.

DNA methylation Quality Control of studies that used 450K array

The QC of 9 studies that used 450K array is previously described in the study of Smith et al.⁴⁸ and available on https://github.com/PGC-PTSD-EWAS/QC Pipeline. Briefly, ß-values, representative of the proportion of methylation at each probe, were calculated for all CpG sites in each sample. Samples with probe detection call rates <90% and those with an average intensity value of either <50% of the experiment-wide sample mean or <2000 arbitrary units (AU) were excluded. Probes with detection p-values > 0.001 or those based on less than three beads were set to missing as were probes that cross-hybridized between autosomes and sex chromosomes⁴⁹. CpG sites with missing data for >10% of samples within cohorts were excluded from analysis. Normalization of probe distribution was conducted using Beta Mixture Quantile Normalization (BMIQ)⁴⁹ after background correction. Density plots of Type I and Type II probes before and after normalization were examined to confirm probe distributions between types were similar. ComBat was used to account for sources of technical variation including batch and positional effects, while preserving variation attributable to study-specific outcomes and covariates that would be used in downstream analyses (e.g., case status or sex). Proportions of CD8, CD4, NK, B cells, monocytes, and granulocytes were estimated using each individual's DNA methylation data based on the approach described by Houseman and colleagues and publicly available reference data (GSE36069)^{50,51}.

Statistical analysis. Within each cohort, logit transformed ß-values (M-values) were modeled by linear regression as a function of PTSD, adjusting for sex (if applicable), age, CD8, CD4, NK, B cell, and monocyte cell proportions, and ancestry using principal components (PCs). For cohorts with available GWAS data (Army STARRS, GTP, INTRUST, MRS, VA-M, VA-NCPTSD), PCs 1-3 were included as covariates. For cohorts without GWAS data (DNHS, PRISMO, WTC), the method described by Barfield and colleagues was used to generate ancestry PCs directly from the methylation data using CpG sites from the HumanMethylation450 array that are located within 0–100 bp of 1000 Genomes Project variants with minor allele frequency > 0.01, and PCs 2–4, which were the components that correlate most with ancestry, were used to adjust for ancestry as recommended by the authors⁵². Using the empirical Bayes method in the R package limma⁵³, moderated t-statistics were calculated for each CpG site, converted first into one-sided p-values then converted into z-scores to account for direction of effects.

Ancestry Principal Components

Ancestry principal components (PCs) were generated directly from DNA methylation data, using CpG sites from the HumanMethylation450 array that are located directly on 1000 Genomes Project variants with minor allele frequency >0.01, following the method described by Barfield

and colleagues⁵² as previously implemented⁵⁴. Consistent with previous reports, PC1 was associated with other factors (e.g., cell type composition, smoking)^{52,55}.

Smoking Score

We used the weights of an EWAS of smoking⁵⁶ to generate smoking score from DNA methylation data. The weights include effect sizes of 39 CpGs that were associated with smoking pack years. We computed smoking score by calculating product of the M values for these 39 CpG sites times the effect size estimates.

Postmortem brain DNAm

National center for PTSD Brain bank (NCPTSD-BB). We examined the associations with PTSD in dIPFC and vmPFC of 42 PTSD cases and 30 controls from the NCPTSD-BB using linear regressions, adjusting for age at death, sex, 3 ancestry PCs and the % neurons as estimated using the CETS package⁵⁷.

PsychENCODE Consortium for PTSD (PEC-PTSD) Brainomics. The associations between DNAm and PTSD in amygdala and DG were tested in 77 PTSD cases and 77 psychopathology-free controls from the PEC-PTSD. Two batches of data were analyzed (batch 1 had 50 cases and 50 controls, while batch 2 had 27 cases and 27 controls). Funnorm (*minfi* package⁵⁸) was used for normalization, *ENmix⁵⁹* for neuronal and non-neuronal cell type proportion estimation, *limma* package⁶⁰ for differential methylation. *Metafor* package⁶¹ was used for fixed-effect meta-analysis of the results from the two batches.

RNAseq Data

BEAR. RNA was isolated by MagMAX for Stabilized Blood Tubes RNA Isolation Kit. All sequenced RNA samples had RNA Integrity Number (RIN) > 7. Library preparation was performed using the Illumina TruSeq Stranded Total RNA With Illumina Ribo-ZeroTM Plus rRNA reduction. The libraries were sequenced using a NextSeq550, which generated paired-end 100 bp reads. STAR is used to perform alignment against the hg38 human reference genome and transcriptome quantification⁶². Quality of the raw, trimmed, and aligned reads were checked using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and MultiQC⁶³ separately. Outlier samples (samples that are 1.5 times the interquartile range less than the first quartile [Q1] or 1.5 times the interquartile range greater than the third quartile [Q3]) in terms of uniquely mapped read counts and percentage of uniquely mapped reads. Self-report sex was confirmed by examining chrX gene *XIST* and chrY genes *EIF1AY, RPS4Y1, DDX3Y*, and *KDM5D*. Reads were normalized by log2 transformation in DEseq2⁶⁴.

MRS. RNA sequencing methods for MRS is described previously⁶⁵. Briefly, RNA was isolated from peripheral blood leukocytes using LeukoLOCK Total RNA isolation. All mRNA samples passed an RNA integrity number (RIN) > 7. mRNA was subjected to Poly-A enrichment and 50bp paired-end sequencing on the Illumina Hi-Seq 2000. RNA libraries were prepared for

sequencing using standard Illumina Tru-Seq protocols. Sequenced reads were trimmed for adaptor sequence and masked for low-complexity or low quality sequence, then mapped to hg19 RefSeq Human Genome and counted using RSEM⁶⁶. Genes with low read counts were filtered in an unspecific manner using edgeR⁶⁷. Genes having > 20 counts per million in at least 50% of the samples were retained. Resulting count data was normalized using the edgeR VOOM function^{67,68} and subjected to clustering analysis and principal component analysis (PCA). Clustering, based on Pearson correlation and average distance metric, was used to spot outliers if outside 2.5 standard deviations from the average. Outliers were removed if outside 2 standard deviations from the average.

AURORA. Blood was collected using PAXgene RNA tubes. Total RNA was isolated using PAXgene blood miRNA kits (Qiagen, Germantown, MD) and RNA was stored at -80 °C until use. RNA concentration and purity were measured using Qubit RNA Assay Kits (ThermoFisher, Waltham, MA) and a 4200 TapeStation System (Agilent Technologies, Santa Clara, CA). The average RNA integrity (RIN) score across the cohort was 7.9, with 92% of samples having a RIN score \geq 7. Four samples had RIN values below 4 and were discarded while the remainder were used to prepare RNA sequencing libraries. Template libraries for total RNA sequencing were produced from 600ng total RNA using Genomics Universal Plus Total RNA Seq Library kits with rRNA and globin depletion (TECAN, Morrisville, NC) according to manufacturer's specifications. Libraries were multiplexed in groups of 96 and sequenced on an NovaSeg S4 200 cycle kit (Illumina, San Diego, CA) using paired end reads (100x) at the University of North Carolina at Chapel Hill High Throughput Sequencing Facility. RNA-seq reads were trimmed, mapped to the hg38 human reference genome using STAR2.7.6a⁶², then quantified using Salmon 1.4.0⁶⁹. Raw read counts were then upper-quantile normalized and log2 transformed. Only genes that had at least 10 reads in any given library were used in subsequent analysis. Outliers were identified via principal component analysis. To verify the appropriate male/female categorization based on genetic attributes, median XIST RNA read counts were compared between women and men.

NCPTSD Merit. The sample consists of 204 participants (52% current PTSD, 85% male, 69% white) with mean (SD) age 56.54 (13.14). RNA was extracted using the Qiagen Paxgene RNA kit. Samples containing sufficient RNA were proceeded for sequencing. The Nanodrop RNA protocol was used to determine RNA concentrations. RNA Integrity (RIN) values for each sample were calculated using a Tapestation 4200 using RNA screen tapes (Agilent, 5067-5576) and buffer (Agilent, 5067-5577). 200 ng of total RNA and 1 ul of a 1:1000 dilution of ERCC RNA Spike-in mix 1 (ThermoFisher, 4456740) was used as input into Illumina TruSeg Stranded Total RNA with Ribo-Zero Globin kit (Illumina, 20020613) for library preparation. The libraries were indexed with IDT for Illumina – TruSeq RNA UD Indexes (Illumina, 20022371). Pooled libraries were sequenced on an Illumina NextSeq 550 sequencer using 150 cycle NextSeq 500/550 High Output Kits v2.5 (Illumina, 20024907) to produce 10-20 million 75-bp paired-end reads per sample. Raw reads were trimmed using Trimmomatic⁷⁰ to eliminate adapters and short or lowquality reads. Trimmed reads were aligned to hg38 human reference genome⁷¹ via STAR⁶². Quality of the raw, trimmed, and aligned reads were checked using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), RSeQC⁷², and MultiQC⁶³ separately. Samples with less than 50% uniquely mapped reads were excluded. Aligned reads

were then quantified using RSEM⁶⁶. Self-report sex was confirmed by examining Y chromosome gene expressions. Raw counts were regularized log (rLog) transformed using DESeq2⁶⁴. Principal Component (PC) of rLog expression values were generated, and outliers were identified and removed if being 6 SDs away from the mean for any of the first 10 PCs. Genotypes were called from the aligned reads using the GATK HaplotypeCaller (https://gatk.broadinstitute.org/hc/en-us/articles/360037225632-HaplotypeCaller) and compared with chip-based genotypes to confirm sample concordance.

eFigure 1. Forest Plots of PTSD-associated CpGs in each cohort. The x-axis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0. Primary meta-analysis is shown in blue and sensitivity analysis for smoking is shown in red.



eFigure 2. Manhattan plots of the stratified analyses. Stratified analysis for A) females, B) males, C) European ancestry, D) African ancestry, E) civilian trauma, and F) military trauma. The x-axis depicts chromosomes and the location of each CpG site across the genome. The y-axis depicts the -log10 of the unadjusted p-value for the association with current PTSD. Each dot represents a CpG site. The solid blue line indicates the epigenome-wide statistical significance at p < 9e-8.





eFigure 3. Forest Plots of CpGs associated with PTSD in the stratified analysis for females. The x-axis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0.



eFigure 4. Forest Plots of CpGs associated with PTSD in the stratified analysis for males. The xaxis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0.



eFigure 5. Forest Plots of CpGs associated with PTSD in the stratified analysis for European ancestry. The x-axis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0.



eFigure 6. Forest Plots of CpGs associated with PTSD in the stratified analysis for African ancestry. The x-axis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0.



eFigure 7. Forest Plots of CpGs associated with PTSD in the stratified analysis for civilian trauma. The x-axis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0.



cg27541344 (BCL11B)

eFigure 8. Forest Plots of CpGs associated with PTSD in the stratified analysis for military trauma. The x-axis is the effect size for each association and includes the 95% confidence interval. Error bars represent the 95% confidence interval, and the center of the error bars represent effect sizes for the CpGs in each cohort. Filled circles indicates a nominally significant association (p < 0.05). Hollow circles indicate the lack of association (p > 0.05). The vertical line indicates an effect size of 0.



			Primary Analysis		Sensitivit	y Analysis
CpG	Position	Gene	Z	<i>p</i> -value	Z	<i>p</i> -value
cg05575921	chr5:373378	AHRR	-6.05	1.44E-09	-3.17	1.52E-03
cg21161138	chr5:399360	AHRR	-5.96	2.50E-09	-1.94	0.053*
cg04583842	chr16:88103117	BANP	5.81	6.29E-09	3.66	2.51E-04
cg14753356	chr6:30720108	Intergenic	-5.72	1.09E-08	-3.62	2.98E-04
cg25320328	chr1:92953037	GFI1	-5.65	1.64E-08	-4.96	7.10E-07
cg26599989	chr11:1297087	TOLLIP	5.58	2.35E-08	4.45	8.58E-06
cg19719391	chr4:26789915	Intergenic	5.58	2.45E-08	5.19	2.10E-07
cg16758086	chr1: 6173356	CHD5	5.55	2.85e-08	4.74	2.15E-06
cg04987734	chr14:103415873	CDC42BPB	5.53	3.26E-08	4.35	1.37E-05
cg23576855	chr5:373299	AHRR	-5.52	3.44E-08	-3.37	7.59E-04
cg09822192	chr14:24801191	ADCY4	5.44	5.30E-08	4.45	8.70E-06

eTable 1. PTSD-associated CpGs from the primary analysis in the sensitivity analysis adjusted for smoking score.

Position is based on hg19. The sites that were not nominally significant (p > 0.05) in the sensitivity analysis adjusted for smoking score were indicated by an asterisk (*).

		Primar	y Analysis	Ν	/lales	Fe	males	Eur	ropean	A	frican	Ci	vilian	М	ilitary
IlmnID	Gene	z	<i>p</i> -value	z	<i>p</i> -value	z	<i>p</i> -value	z	<i>p</i> -value	z	p-value	z	<i>p</i> -value	z	<i>p</i> -value
cg05575921	AHRR	-6.05	1.44E-09	-6.12	9.30E-10	-2.21	2.72E-02	-6.85	7.24E-12	-1.22	2.21E-01*	-1.79	7.42E-02*	-6.22	4.92E-10
cg21161138	AHRR	-5.96	2.50E-09	-5.09	3.59E-07	-3.52	4.35E-04	-5.62	1.95E-08	-1.65	9.85E-02*	-3.26	1.11E-03	-4.88	1.07E-06
cg04583842	BANP	5.81	6.29E-09	4.08	4.50E-05	4.40	1.07E-05	5.43	5.66E-08	3.20	1.39E-03	3.23	1.22E-03	4.99	5.95E-07
cg14753356	Intergenic	-5.72	1.09E-08	-4.89	1.01E-06	-3.07	2.18E-03	-4.82	1.45E-06	-1.39	1.65E-01*	-1.88	6.04E-02*	-5.47	4.53E-08
cg25320328	GFI1	-5.65	1.64E-08	-4.08	4.59E-05	-3.82	1.35E-04	-4.99	6.15E-07	-2.08	3.71E-02	-3.78	1.55E-04	-4.37	1.24E-05
cg26599989	TOLLIP	5.58	2.35E-08	4.64	3.49E-06	2.78	5.51E-03	4.38	1.19E-05	3.20	1.39E-03	2.14	3.27E-02	5.13	2.94E-07
cg19719391	Intergenic	5.58	2.45E-08	3.71	2.06E-04	4.07	4.79E-05	4.27	1.98E-05	3.37	7.43E-04	4.54	5.53E-06	3.59	3.34E-04
cg16758086	CHD5	5.55	2.85E-08	4.81	1.49E-06	2.78	5.44E-03	5.08	3.74E-07	2.40	1.65E-02	2.60	9.38E-03	4.97	6.68E-07
cg04987734	CDC42BPB	5.53	3.26E-08	3.59	3.27E-04	3.74	1.83E-04	3.66	2.49E-04	5.27	1.38E-07	4.15	3.29E-05	3.81	1.39E-04
cg23576855	AHRR	-5.52	3.44E-08	-4.53	6.01E-06	-3.62	2.97E-04	-4.05	5.06E-05	-2.09	3.67E-02	-3.27	1.07E-03	-4.43	9.61E-06
cg09822192	ADCY4	5.44	5.30E-08	4.78	1.73E-06	2.15	3.12E-02	4.53	5.81E-06	2.03	4.27E-02	3.59	3.28E-04	4.40	1.06E-05
cg25691167	FERD3L	3.57	3.60E-04	0.57	5.67E-01*	5.48	4.24E-08	2.51	1.21E-02	3.19	1.43E-03	4.05	5.12E-05	1.50	1.33E-01*
cg11256214	MGC14436	4.83	1.36E-06	4.99	5.95E-07	1.45	1.47E-01*	5.76	8.17E-09	1.50	1.34E-01*	1.17	2.42E-01*	5.00	5.80E-07
cg15977432	Intergenic	-3.59	3.31E-04	-3.51	4.56E-04	-1.34	1.81E-01*	-5.46	4.68E-08	-0.87	3.87E-01*	-0.49	6.27E-01*	-3.51	4.55E-04
cg02003183	CDC42BPB	3.99	6.65E-05	2.22	2.63E-02	3.79	1.52E-04	2.33	1.98E-02	5.48	4.26E-08	3.19	1.43E-03	2.74	6.18E-03
cg27541344	BCL11B	3.96	7.38E-05	2.13	3.33E-02	3.49	4.74E-04	1.43	1.54E-01*	3.54	3.95E-04	5.39	7.21E-08	0.88	3.77E-01*
cg00774777	RP11-21L23.4	4.93	8.24E-07	5.20	2.02E-07	1.09	2.77E-01*	5.09	3.67E-07	0.75	4.56E-01*	0.71	4.76E-01*	5.55	2.79E-08
cg21566642	Intergenic	-5.25	1.52E-07	-5.28	1.29E-07	-2.23	2.56E-02	-5.08	3.85E-07	-1.06	2.87E-01*	-1.31	1.89E-01*	-5.41	6.36E-08
cg03329539	Intergenic	-5.02	5.27E-07	-4.90	9.70E-07	-2.10	3.61E-02	-4.06	4.83E-05	-0.86	3.88E-01*	-1.01	3.12E-01*	-5.36	8.53E-08

eTable 2. PTSD-associated CpGs from the primary analysis in the stratified analysis for sex, ancestry, and trauma type.

Epigenome-wide significant sites (p < 9e-08) were shown in bold. Non-significant sites (p > 0.05) were indicated by an asterisk (*).

eTable 3. Gene Ontology Enrichment results in females.

GO ID	GO term	Ν	DE	P.DE	FDR
GO:0007399	nervous system development	2474	175	7.34E-09	1.17E-04
GO:0048731	system development	3971	238	5.27E-08	4.20E-04
GO:0007275	multicellular organism development	4643	260	6.16E-07	3.27E-03

GO: Gene Ontology. N: Number of genes in the GO term. DE: Number of genes that are differentially methylated. P.DE: p-value for over-representation of the GO term. FDR: False discovery rate.

		I	PFC		EC		STG		CER	
CpG	Gene	r	<i>p</i> -value							
cg05575921	AHRR	0.280	0.016	0.194	0.104	0.208	0.0735	-0.008	0.948	
cg21161138	AHRR	0.177	0.131	0.142	0.239	0.282	0.014	-0.084	0.486	
cg04583842	BANP	-0.181	0.122	0.126	0.297	0.390	5.48e-04	0.001	0.990	
cg14753356	Intergenic	0.050	0.673	0.066	0.583	0.102	0.382	-0.044	0.713	
cg25320328	GFI1	0.198	0.091	-0.148	0.217	0.009	0.939	0.009	0.938	
cg26599989	TOLLIP	0.0505	0.669	-0.074	0.539	0.177	0.129	0.160	0.183	
cg19719391	Intergenic	0.148	0.208	0.256	0.031	-0.001	0.992	0.102	0.397	
cg16758086	CHD5	NA	NA	NA	NA	NA	NA	NA	NA	
cg04987734	CDC42BPB	-0.053	0.652	0.108	0.369	0.184	0.114	-0.021	0.865	
cg23576855	AHRR	0.906	1.51e-28	0.86	6.85e-22	0.890	1.18e-26	0.867	1.39e-22	
cg09822192	ADCY4	0.142	0.226	0.179	0.136	0.053	0.653	0.223	0.062	
cg25691167	FERD3L	-0.056	0.637	0.022	0.855	-0.107	0.363	-0.211	0.078	
cg11256214	MGC14436	-0.058	0.623	0.052	0.670	0.040	0.731	0.033	0.786	
cg15977432	Intergenic	0.751	1.37e-14	0.799	6.43e-17	0.808	1.95e-18	0.754	3.32e-14	
cg02003183	CDC42BPB	0.130	0.268	0.192	0.108	0.263	0.023	0.144	0.232	
cg27541344	BCL11B	NA	NA	NA	NA	NA	NA	NA	NA	
cg00774777	RP11-21L23.4	NA	NA	NA	NA	NA	NA	NA	NA	
cg21566642	Intergenic	0.386	6.82e-04	0.384	9.39e-04	0.508	3.28e-06	0.117	0.329	
cg03329539	Intergenic	-0.065	0.58	-0.057	0.639	0.301	0.009	0.173	0.143	

eTable 4. Correlation values of methylation between blood and brain regions from Blood Brain DNA Methylation Comparison Tool.

The list includes CpGs identified from the primary meta-analysis and the stratified analyses for sex, ancestry, and trauma type. PFC: prefrontal cortex. EC: entorhinal cortex. STG: superior temporal gyrus. CER: cerebellum. NA indicates that CpG is not available in the Blood Brain DNA Methylation Comparison Tool. Significant correlations are shown in bold.

			dIPFC		nPFC	Amy	/gdala	DG		
CpG	Gene	logFC	<i>p</i> -value							
cg05575921	AHRR	-0.03	0.725	-0.06	0.451	-0.01	0.922	0.16	0.127	
cg21161138	AHRR	-0.24	5.92E-03	0.06	0.512	0.01	0.937	-0.09	0.186	
cg04583842	BANP	0.08	0.466	0.04	0.612	0.04	0.630	-0.06	0.495	
cg14753356	Intergenic	0.25*	7.60E-03	0.25*	0.016	0.15	0.110	0.04	0.638	
cg25320328	GFI1	0.18*	0.036	-0.06	0.453	-0.03	0.544	-0.02	0.787	
cg26599989	TOLLIP	-0.06	0.427	-0.03	0.625	-0.08	0.077	-0.02	0.631	
cg19719391	Intergenic	0.08	0.353	0.09	0.329	-0.02	0.664	0.16	0.003	
cg16758086	CHD5	0.02	0.856	0.03	0.818	0.05	0.475	-0.06	0.400	
cg04987734	CDC42BPB	0.20	3.90E-03	0.05	0.445	0.05	0.527	0.08	0.209	
cg23576855	AHRR	-0.06	0.699	-0.10	0.527	NA	NA	NA	NA	
cg09822192	ADCY4	0.02	0.746	-0.04	0.581	0.04	0.332	0.00	0.952	
cg25691167	FERD3L	-0.09	0.249	-0.02	0.784	-0.10	0.398	0.07	0.494	
cg11256214	MGC14436	0.02	0.812	0.12	0.054	0.01	0.748	-0.05	0.119	
cg15977432	Intergenic	-0.69	0.154	-0.23	0.640	NA	NA	NA	NA	
cg02003183	CDC42BPB	0.17	0.192	0.07	0.557	0.16	0.060	0.07	0.551	
cg27541344	BCL11B	0.04	0.662	-0.05	0.708	0.02	0.786	-0.10	0.196	
cg00774777	RP11-21L23.4	-0.16	0.152	0.01	0.938	0.15	0.039	0.33	3.79E-06	
cg21566642	Intergenic	-0.13	0.112	-0.09	0.274	0.00	0.991	0.21*	6.86E-03	
cg03329539	Intergenic	-0.07	0.294	0.15	0.082	-0.11	0.055	-0.08	0.191	

eTable 5. Results of PTSD-associated CpGs from blood in the brain.

The list includes CpGs identified from the primary meta-analysis and the stratified analyses for sex, ancestry, and trauma type. dlPFC: dorsolateral prefrontal cortex. vmPFC: ventromedial prefrontal cortex. DG: dentate gyrus. logFC: logarithm of fold change. NA indicates that CpG was not available in the post-mortem brain dataset. Significant associations with PTSD are shown in bold. Sites with an opposite direction of association in the brain were indicated with an asterisk (*).

eTable 6. Results of PTSD-associated CpGs from blood in neuronal nuclei.

				5mC 5l				hmC		
CpG	Position	Gene	Position	ΔDNAm	<i>p</i> -value	Position	ΔDNAm	<i>p</i> -value		
cg05575921	chr5:373263	AHRR	chr5:373668	-2.21	4.84E-04	chr5:373710	5.29*	2.57E-03		
			chr5:373673	1.37*	9.11E-03					
cg21161138	chr5:399245	AHRR	chr5:399720	-3.40	0.045					
cg25691167	chr7:19145338	FERD3L	chr7:19145258	0.67	3.25E-03					
cg21566642	chr2:232419951	Intergenic	chr2:232419004	0.47*	0.026	chr2:232418992	0.37*	0.045		
			chr2:232419552	-2.07	4.17E-03	chr2:232419019	0.67*	0.014		
			chr2:232419868	-2.37	0.022	chr2:232419555	-1.97	0.026		
						chr2:232419980	5.96*	0.016		
						chr2:232419981	-5.56	0.047		

Only significant associations were shown. Neuronal nuclei 5mC and 5hmC results span 500 bp upstream and downstream of PTSDassociated CpGs from blood. 5mC: 5-Methylcytosine. 5hmC: 5-Hydroxymethylcytosine. ΔDNAm: Mean DNA methylation difference between PTSD cases and controls. Position is based on hg38. Sites with an opposite direction of association in neuronal nuclei were indicated with an asterisk (*).

CpG	Gene	ΔDNAm	t	<i>p</i> -value
cg05575921	AHRR	-0.005	-0.67	0.52
cg21161138	AHRR	0.225*	15.55	5.76E-07
cg04583842	BANP	-0.003	-0.44	0.68
cg14753356	Intergenic	0.012	0.81	0.44
cg25320328	GFI1	0.024*	2.42	0.04
cg26599989	TOLLIP	0.067	6.40	1.31E-04
cg19719391	Intergenic	0.057	5.27	4.01E-04
cg16758086	CHD5	0.101	6.67	7.11E-04
cg04987734	CDC42BPB	0.015	1.65	0.14
cg23576855	AHRR	NA	NA	NA
cg09822192	ADCY4	0.025	0.93	0.39
cg25691167	FERD3L	0.104	5.26	6.53E-04
cg11256214	MGC14436	0.114	6.94	5.76E-04
cg15977432	Intergenic	NA	NA	NA
cg02003183	CDC42BPB	-0.010	-0.53	0.61
cg27541344	BCL11B	-0.003	-0.11	0.91
cg00774777	RP11-21L23.4	0.005	0.94	0.37
cg21566642	Intergenic	-0.001	-0.05	0.96
cg03329539	Intergenic	-0.034	-1.69	0.15

eTable 7. Results of PTSD-associated CpGs from blood in fibroblasts.

The list includes CpGs identified from the primary meta-analysis and the stratified analyses for sex, ancestry, and trauma type. Δ DNAm: Mean DNA methylation difference between glucocorticoid treatment and vehicle. NA indicates that CpG was not available in the fibroblast dataset. Significant associations with PTSD are shown in bold. Sites with an opposite direction of association in the fibroblasts were indicated with an asterisk (*).

		l	BEAR	А	URORA		MRS	NCP	TSD Merit	Meta	-Analysis
CpG	Gene	r	<i>p</i> -value	Z	<i>p</i> -value						
cg05575921	AHRR	-0.18	0.04	-0.67	<2.20E-16	-0.6	3.25E-36	-0.38	2.71E-08	-16.69	1.67E-62
cg21161138	AHRR	-0.02	0.80	-0.59	<2.20E-16	-0.48	4.04E-21	-0.29	2.65E-05	-12.45	1.36E-35
cg04583842	BANP	0.22	0.01	-0.04	0.59	0.2	1.65E-04	-0.12	0.10	2.35	1.88E-02
cg14753356	Intergenic	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg25320328	GFI1	0.09	0.30	-0.14	0.07	0.16	2.27E-03	-0.12	0.08	0.69	0.49
cg26599989	TOLLIP	-0.06	0.52	-0.21	0.007	-0.07	0.21	0.03	0.64	-2.14	3.20E-02
cg19719391	Intergenic	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg16758086	CHD5	-0.17	0.05	-0.01	0.9	NA	NA	-0.02	0.73	-1.21	0.22
cg04987734	CDC42BPB	0.20	0.02	0.08	0.28	-0.08	0.13	-0.05	0.48	0.01	0.99
cg23576855	AHRR	0.01	0.94	NA	NA	-0.23	1.73E-05	-0.22	1.74E-03	-4.86	1.18E-06
cg18846074	ADCY4	0.13	0.14	0.05	0.52	-0.15	5.63E-03	-0.07	0.35	-1.47	0.14
cg25691167	FERD3L	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg11256214	MGC14436	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg15977432	Intergenic	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg02003183	CDC42BPB	0.10	0.27	0.12	0.12	-0.09	0.10	-0.12	0.10	-0.80	0.43
cg27541344	BCL11B	-0.56	5.41E-12	-0.52	3.49E-13	NA	NA	-0.50	1.54E-14	-12.89	4.90E-38
cg00774777	RP11-21L23.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg21566642	Intergenic	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cg03329539	Intergenic	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

eTable 8. Blood DNA methylation and cis-gene expression (RNAseq) correlations.

The list includes CpGs identified from the primary meta-analysis and the stratified analyses for sex, ancestry, and trauma type. NA indicates that CpGs or genes were not available in the datasets. Significant correlations are shown in bold.

						meQTL Analysis					GWAS			
CpG	CpG Location	Gene	SNP	MAF	SNP Location	A1	Beta	SE	<i>p</i> -value	Source	A1	A2	z	<i>p</i> -value
cg05575921	chr5:373378	AHRR	rs35947614	0.06	chr5:224397	G	0.23	0.01	<5E-324	GoDMC	А	G	0.27	0.79
cg05575921	chr5:373378	AHRR	rs11958189	0.11	chr5:398696	А	0.25	0.05	7.23E-08	meQTL EPIC	А	G	-0.87	0.39
cg21161138	chr5:399360	AHRR	rs2434697	0.21	chr5:466811	Т	-0.16	0.01	<5E-324	GoDMC	Т	С	-1.68	0.09
cg04583842	chr16:88103117	BANP	rs13331671	0.15	chr16:88009179	А	-0.13	0.02	3.26E-13	GoDMC	NA	NA	NA	NA
cg04583842	chr16:88103117	BANP	rs8050099	0.26	chr16:87319096	Т	-0.35	0.07	1.11E-06	meQTL EPIC	Т	G	1.01	0.31
cg04583842	chr16:88103117	BANP	rs7194688	0.25	chr16:87322169	С	-0.32	0.07	1.60E-05	meQTL EPIC	т	С	-1.21	0.23
cg14753356	chr6:30720108	Intergenic	rs28986310	0.05	chr6:29735797	Т	0.31	0.02	<5E-324	GoDMC	Т	С	6.73	1.68E-11
cg14753356	chr6:30720108	Intergenic	rs562745472	0.05	chr6:30774269	G	0.26	0.03	<5E-324	GoDMC	NA	NA	NA	NA
cg14753356	chr6:30720108	Intergenic	rs2524212	0.38	chr6:30345871	С	-0.16	0.03	1.64E-06	meQTL EPIC	NA	NA	NA	NA
cg14753356	chr6:30720108	Intergenic	rs28780104	0.08	chr6:30424655	G	0.46	0.06	2.34E-14	meQTL EPIC	С	G	-5.33	9.96E-08
cg14753356	chr6:30720108	Intergenic	rs13214831	0.26	chr6:30731505	А	0.49	0.04	4.08E-33	meQTL EPIC	А	G	4.96	7.23E-07
cg14753356	chr6:30720108	Intergenic	rs377098668	<0.001	chr6:30748618	delA	0.34	0.04	2.32E-21	meQTL EPIC	NA	NA	NA	NA
cg14753356	chr6:30720108	Intergenic	rs3131063	0.44	chr6:30763756	А	-0.20	0.04	1.26E-08	meQTL EPIC	А	G	-2.27	2.33E-02
cg14753356	chr6:30720108	Intergenic	rs12206683	0.42	chr6:30771086	С	0.17	0.03	1.38E-06	meQTL EPIC	Т	С	-2.98	2.92E-03
cg14753356	chr6:30720108	Intergenic	rs9468851	0.50	chr6:30930633	G	0.15	0.04	5.40E-05	meQTL EPIC	NA	NA	NA	NA
cg14753356	chr6:30720108	Intergenic	rs2077492	0.50	chr6:31606392	А	0.12	0.03	8.79E-05	meQTL EPIC	А	G	3.78	1.60E-04
cg25320328	chr1:92953037	GFI1	rs11809700	0.27	chr1:93152635	Т	-0.09	0.01	<5E-324	GoDMC	Т	С	-0.83	0.40
cg26599989	chr11:1297087	TOLLIP	rs56139112	0.05	chr11:1257886	Т	-1.12	0.03	<5E-324	GoDMC	Т	С	-1.17	0.24
cg26599989	chr11:1297087	TOLLIP	rs55902810	0.06	chr11:1248723	Т	-0.55	0.07	7.91E-16	meQTL EPIC	Т	С	-0.50	0.62
cg26599989	chr11:1297087	TOLLIP	rs5743987	0.08	chr11:1305846	Т	-0.70	0.06	2.49E-32	meQTL EPIC	Т	С	-0.54	0.59
cg26599989	chr11:1297087	TOLLIP	rs5743936	0.26	chr11:1316431	G	0.42	0.05	1.31E-16	meQTL EPIC	А	G	-0.59	0.56
cg26599989	chr11:1297087	TOLLIP	rs5743899	0.34	chr11:1323564	Т	0.21	0.04	4.06E-08	meQTL EPIC	Т	С	0.42	0.68
cg26599989	chr11:1297087	TOLLIP	rs187976925	0.03	chr11:1420541	G	-0.46	0.10	2.80E-06	meQTL EPIC	NA	NA	NA	NA
cg19719391	chr4:26789915	Intergenic	rs114362105	0.006	chr4:26573525	Т	-0.70	0.05	5.98E-49	GoDMC	Т	С	-1.43	0.15
cg19719391	chr4:26789915	Intergenic	rs17639483	0.34	chr4:26422507	А	0.16	0.03	1.14E-06	meQTL EPIC	А	G	-2.10	3.61E-02

eTable 9. Significant SNPs from cis-meQTL analysis and their association with PTSD.

cg19719391	chr4:26789915	Intergenic	rs12646334	0.47	chr4:26824285	А	-0.25	0.05	5.38E-07	meQTL EPIC	А	G	-0.76	0.45
cg09822192	chr14:24801191	ADCY4	rs112679565	0.05	chr14:24661174	Т	-0.49	0.01	<5E-324	GoDMC	Т	С	0.87	0.38
cg09822192	chr14:24801191	ADCY4	rs2255591	0.35	chr14:24901844	А	-0.14	0.01	3.24E-47	GoDMC	А	G	0.87	0.38
cg09822192	chr14:24801191	ADCY4	rs2243891	0.15	chr14:24846757	А	0.47	0.02	3.13E-182	GoDMC	А	G	0.06	0.95
cg09822192	chr14:24801191	ADCY4	rs17101367	0.33	chr14:24587667	Т	-0.35	0.05	1.84E-13	meQTL EPIC	Т	С	0.21	0.83
cg09822192	chr14:24801191	ADCY4	chr14:24661633	NA	chr14:24661633	G	0.42	0.08	2.90E-08	meQTL EPIC	NA	NA	NA	NA
cg09822192	chr14:24801191	ADCY4	rs60283052	0.24	chr14:24752137	Т	-0.70	0.06	9.41E-30	meQTL EPIC	NA	NA	NA	NA
cg09822192	chr14:24801191	ADCY4	rs10483285	0.07	chr14:24799358	А	0.84	0.08	4.43E-27	meQTL EPIC	А	С	-3.56	3.73E-04
cg09822192	chr14:24801191	ADCY4	rs2042052383	<0.001	chr14:24801443	С	-0.67	0.04	3.97E-58	meQTL EPIC	NA	NA	NA	NA
cg09822192	chr14:24801191	ADCY4	rs11621792	0.23	chr14:24871926	Т	0.38	0.04	5.87E-23	meQTL EPIC	Т	С	-0.48	0.63
cg09822192	chr14:24801191	ADCY4	rs200457643	<0.001	chr14:25188870	ATG	0.15	0.03	3.18E-06	meQTL EPIC	NA	NA	NA	NA
cg25691167	chr7:19184961	FERD3L	rs12700019	0.21	chr7:19186886	С	0.18	0.01	3.15E-40	GoDMC	С	G	-1.55	0.12
cg11256214	chr12:110211642	MGC14436	rs11614658	0.18	chr12:110082320	С	-0.41	0.08	3.98E-07	meQTL EPIC	Т	С	0.01	0.9903
cg00774777	chr11:76478902	RP11-21L23.4	rs12794131	0.14	chr11:76456739	Т	-0.37	0.04	1.44E-18	meQTL EPIC	Т	С	-1.05	0.2921
cg00774777	chr11:76478902	RP11-21L23.4	rs60651758	0.096	chr11:76469378	А	0.50	0.11	1.32E-05	meQTL EPIC	А	G	-0.32	0.7519
cg21566642	chr2:233284661	Intergenic	chr2:233221796	0.11	chr2:233221796	delT	-0.20	0.02	<5E-183	GoDMC	NA	NA	NA	NA

Only significant (p < 1E-08 for GoDMC and p < 2.21E-04 for meQTL EPIC database) methylation quantitative trait loci (meQTL) were shown. All meQTLs are cis. No trans-meQTLs were identified. GWAS results are obtained from the Freeze 3 GWAS from Psychiatric Genomics Consortium PTSD Workgroup (PGC-PTSD)⁷³. MAF column shows minor allele frequency from 1000Genomes phase 3 Global population. A1 indicates effect (tested) allele and A2 indicates alternative (reference) allele. D in A1 column indicates deletion. Beta: Linear regression beta coefficient. SD: Standard deviation. NA indicates that SNP was not available in the PGC-PTSD Freeze 3 GWAS summary statistics⁷³. Significant GWAS results (p < 0.05) are shown in bold. Positions are based on hg19.

Gene	Chr	Start	Stop	NSNPs	Z	<i>p</i> -value
AHRR	5	304,291	438,406	390	2.70	3.48E-03
BANP	16	87,982,850	88,110,924	542	-0.18	0.57
GFI1	1	92,940,319	92,952,433	20	0.99	0.16
TOLLIP	11	1,295,601	1,330,884	108	-0.15	0.56
CHD5	1	6,161,853	6,240,183	252	-0.61	0.73
CDC42BPB	14	103,398,716	103,523,799	283	3.20	6.94E-04
ADCY4	14	24,787,555	24,804,299	50	0.55	0.29
FERD3L	NA	NA	NA	NA	NA	NA
MGC14436	NA	NA	NA	NA	NA	NA
BCL11B	14	99,635,624	99,737,861	241	3.87	5.40E-05
RP11-21L23.4	NA	NA	NA	NA	NA	NA

eTable 10. Genetic associations of the identified PTSD-associated genes from gene-based tests.

Gene based test results are obtained from the Freeze 3 GWAS from PGC-PTSD⁷³. Chr: chromosome. Start: Gene start position. Stop: Gene stop position. NSNPs: number of SNPs annotated to gene and used in the analysis. Significant results (p < 0.05) are shown in bold.

References

1. Nugent NR, Armey M, Boker S, et al. Adolescents hospitalised for suicidality: biomarkers, social and affective predictors: a cohort study. *BMJ Open*. 2022;12(10):e056063. doi:10.1136/bmjopen-2021-056063

2. Weathers F, Blake D, Schnurr P, Kaloupek D, Marx B, Keane T. The life events checklist for DSM-5 (LEC-5). 2013;

3. Pynoos R, Weathers F, Steinberg A, et al. Clinician-Administered PTSD Scale for DSM-5 - Child/Adolescent Version. 2015;

4. Uddin M, Aiello AE, Wildman DE, et al. Epigenetic and immune function profiles associated with posttraumatic stress disorder. *Proc Natl Acad Sci U S A*. May 18 2010;107(20):9470-5. doi:10.1073/pnas.0910794107

5. Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of the PTSD Checklist (PCL). *Behav Res Ther*. Aug 1996;34(8):669-73. doi:10.1016/0005-7967(96)00033-2

6. Stein DJ, Koen N, Donald KA, et al. Investigating the psychosocial determinants of child health in Africa: The Drakenstein Child Health Study. *J Neurosci Methods*. Aug 30 2015;252:27-35. doi:10.1016/j.jneumeth.2015.03.016

7. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. *European psychiatry*. 1997;12(5):224-231.

8. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *The Journal of Clinical Psychiatry*. 1998;59(Suppl 20):22-33.

9. Gillespie CF, Bradley B, Mercer K, et al. Trauma exposure and stress-related disorders in inner city primary care patients. *Gen Hosp Psychiatry*. Nov-Dec 2009;31(6):505-14. doi:10.1016/j.genhosppsych.2009.05.003

10. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. *J Trauma Stress*. Jan 1995;8(1):75-90. doi:10.1007/BF02105408

11. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the first ten years of research. *Depress Anxiety*. 2001;13(3):132-56. doi:10.1002/da.1029

12. Falsetti SA, Resnick HS, Resick PA, Kilpatrick DG. The Modified PTSD Symptom Scale: A brief self-report measure of posttraumatic stress disorder. *the Behavior Therapist*. 1993;16:161-162.

13. Kubany ES, Leisen MB, Kaplan AS, Kelly MP. Validation of a brief measure of posttraumatic stress disorder: the Distressing Event Questionnaire (DEQ). *Psychol Assess*. Jun 2000;12(2):197-209. doi:10.1037//1040-3590.12.2.197

14. van den Heuvel LL, Stalder T, du Plessis S, Suliman S, Kirschbaum C, Seedat S. Hair cortisol levels in posttraumatic stress disorder and metabolic syndrome. *Stress*. Sep 2020;23(5):577-589. doi:10.1080/10253890.2020.1724949

15. Weathers FW, Bovin MJ, Lee DJ, et al. Clinician-administered ptsd scale for DSM-5. *Psychological Assessment*. 2015;

16. Weathers F, Litz B, Keane T, Palmieri P, Marx B, Schnurr P. The PTSD Checklist for DSM-5 (PCL-5). 2013. <u>www.ptsd.va.gov</u>

17. Bernstein DP, Fink L. *Childhood Trauma Questionnaire: A retrospective self-report manual*. The Psychological Corporation; 1998.

18. McLean SA, Ressler K, Koenen KC, et al. The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. *Mol Psychiatry*. Feb 2020;25(2):283-296. doi:10.1038/s41380-019-0581-3

19. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *J Trauma Stress*. Dec 2015;28(6):489-98. doi:10.1002/jts.22059

20. Kessler RC, Ressler KJ, House SL, et al. Socio-demographic and trauma-related predictors of PTSD within 8 weeks of a motor vehicle collision in the AURORA study. *Mol Psychiatry*. Jul 2021;26(7):3108-3121. doi:10.1038/s41380-020-00911-3

21. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. *Psychol Assess*. Nov 2016;28(11):1379-1391. doi:10.1037/pas0000254

22. Perroud N, Rutembesa E, Paoloni-Giacobino A, et al. The Tutsi genocide and transgenerational transmission of maternal stress: epigenetics and biology of the HPA axis. *World J Biol Psychiatry*. May 2014;15(4):334-45. doi:10.3109/15622975.2013.866693

23. Musanabaganwa C, Wani AH, Donglasan J, et al. Leukocyte methylomic imprints of exposure to the genocide against the Tutsi in Rwanda: a pilot epigenome-wide analysis. *Epigenomics*. Jan 2022;14(1):11-25. doi:10.2217/epi-2021-0310

24. Mulder N, Abimiku A, Adebamowo SN, et al. H3Africa: current perspectives. *Pharmgenomics Pers Med*. 2018;11:59-66. doi:10.2147/PGPM.S141546

25. Weathers F, Ford J, Stamm B. Measurement of stress, trauma, and adaptation. *Psychometric Review of PTSD Checklist (PCL-C, PCL-S PCL-M, PCL-PR)*. 1996:250-251.

26. Weathers F, Litz B, Keane T, Palmieri P, Marx B, Schnurr P. The PTSD checklist for DSM-5 (PCL-5)–LEC-5 and extended criterion a [Measurement instrument]. *Avaliable from <u>http://www</u> ptsd va gov.* 2013;

27. Herbert R, Moline J, Skloot G, et al. The World Trade Center disaster and the health of workers: five-year assessment of a unique medical screening program. *Environ Health Perspect*. Dec 2006;114(12):1853-8. doi:10.1289/ehp.9592

28. Bromet EJ, Hobbs MJ, Clouston SA, Gonzalez A, Kotov R, Luft BJ. DSM-IV post-traumatic stress disorder among World Trade Center responders 11-13 years after the disaster of 11 September 2001 (9/11). *Psychol Med*. Mar 2016;46(4):771-83.

doi:10.1017/S0033291715002184

29. Kuan PF, Waszczuk MA, Kotov R, et al. An epigenome-wide DNA methylation study of PTSD and depression in World Trade Center responders. *Transl Psychiatry*. Jun 27 2017;7(6):e1158. doi:10.1038/tp.2017.130

30. Mehta D, Bruenig D, Carrillo-Roa T, et al. Genomewide DNA methylation analysis in combat veterans reveals a novel locus for PTSD. *Acta Psychiatr Scand*. Nov 2017;136(5):493-505. doi:10.1111/acps.12778

31. Nievergelt CM, Maihofer AX, Mustapic M, et al. Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. *Psychoneuroendocrinology*. Jan 2015;51:459-71. doi:10.1016/j.psyneuen.2014.10.017

32. Baker DG, Nash WP, Litz BT, et al. Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. *Prev Chronic Dis.* 2012;9:E97. doi:10.5888/pcd9.110134

33. Reijnen A, Rademaker AR, Vermetten E, Geuze E. Prevalence of mental health symptoms in Dutch military personnel returning from deployment to Afghanistan: a 2-year longitudinal analysis. *Eur Psychiatry*. Feb 2015;30(2):341-6. doi:10.1016/j.eurpsy.2014.05.003

34. Eekhout I, Reijnen A, Vermetten E, Geuze E. Post-traumatic stress symptoms 5 years after military deployment to Afghanistan: an observational cohort study. *Lancet Psychiatry*. Jan 2016;3(1):58-64. doi:10.1016/S2215-0366(15)00368-5

35. Hovens JE, Bramsen I, van der Ploeg HM. Self-rating inventory for posttraumatic stress disorder: review of the psychometric properties of a new brief Dutch screening instrument. *Percept Mot Skills*. Jun 2002;94(3 Pt 1):996-1008. doi:10.2466/pms.2002.94.3.996

36. van Zuiden M, Geuze E, Willemen HL, et al. Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. *Am J Psychiatry*. Jan 2011;168(1):89-96. doi:10.1176/appi.ajp.2010.10050706

37. Rutten BPF, Vermetten E, Vinkers CH, et al. Longitudinal analyses of the DNA methylome in deployed military servicemen identify susceptibility loci for post-traumatic stress disorder. *Mol Psychiatry*. May 2018;23(5):1145-1156. doi:10.1038/mp.2017.120

38. Ursano RJ, Colpe LJ, Heeringa SG, et al. The Army study to assess risk and resilience in servicemembers (Army STARRS). *Psychiatry*. Summer 2014;77(2):107-19. doi:10.1521/psyc.2014.77.2.107

39. Kessler RC, Santiago PN, Colpe LJ, et al. Clinical reappraisal of the Composite International Diagnostic Interview Screening Scales (CIDI-SC) in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). *Int J Methods Psychiatr Res*. Dec 2013;22(4):303-21. doi:10.1002/mpr.1398

40. Rauch SAM, Kim HM, Powell C, et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. Feb 1 2019;76(2):117-126. doi:10.1001/jamapsychiatry.2018.3412

41. Rauch SAM, Simon NM, Kim HM, et al. Integrating biological treatment mechanisms into randomized clinical trials: Design of PROGrESS (PROlonGed ExpoSure and Sertraline Trial). *Contemp Clin Trials*. Jan 2018;64:128-138. doi:10.1016/j.cct.2017.10.013

42. Logue MW, Baldwin C, Guffanti G, et al. A genome-wide association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus. *Mol Psychiatry*. Aug 2013;18(8):937-42. doi:10.1038/mp.2012.113
43. Wolf EJ, Miller MW, Hawn SE, et al. Longitudinal study of traumatic-stress related cellular and cognitive aging. (under review);

44. McGlinchey RE, Milberg WP, Fonda JR, Fortier CB. A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study. *Int J Methods Psychiatr Res*. Sep 2017;26(3)doi:10.1002/mpr.1556

45. Weathers FW, Bovin MJ, Lee DJ, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. *Psychol Assess*. Mar 2018;30(3):383-395. doi:10.1037/pas0000486

46. Kubany ES, Haynes SN, Leisen MB, et al. Development and preliminary validation of a brief broad-spectrum measure of trauma exposure: the Traumatic Life Events Questionnaire. *Psychol Assess*. Jun 2000;12(2):210-24. doi:10.1037//1040-3590.12.2.210

47. Ashley-Koch AE, Garrett ME, Gibson J, et al. Genome-wide association study of posttraumatic stress disorder in a cohort of Iraq-Afghanistan era veterans. *J Affect Disord*. Sep 15 2015;184:225-34. doi:10.1016/j.jad.2015.03.049

48. Smith AK, Ratanatharathorn A, Maihofer AX, et al. Epigenome-wide meta-analysis of PTSD across 10 military and civilian cohorts identifies methylation changes in AHRR. *Nat Commun*. Nov 24 2020;11(1):5965. doi:10.1038/s41467-020-19615-x

49. Teschendorff AE, Marabita F, Lechner M, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics*. Jan 15 2013;29(2):189-96. doi:10.1093/bioinformatics/bts680

50. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics*. May 8 2012;13:86. doi:10.1186/1471-2105-13-86

51. Reinius LE, Acevedo N, Joerink M, et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. *PLoS One*. 2012;7(7):e41361. doi:10.1371/journal.pone.0041361

52. Barfield RT, Almli LM, Kilaru V, et al. Accounting for population stratification in DNA methylation studies. *Genet Epidemiol*. Apr 2014;38(3):231-41. doi:10.1002/gepi.21789

53. Smyth GK. limma: Linear Models for Microarray Data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, eds. *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*. Springer New York; 2005:397-420.

54. Katrinli S, Maihofer AX, Wani AH, et al. Epigenome-wide meta-analysis of PTSD symptom severity in three military cohorts implicates DNA methylation changes in genes involved in immune system and oxidative stress. *Mol Psychiatry*. Mar 2022;27(3):1720-1728. doi:10.1038/s41380-021-01398-2

55. Rahmani E, Shenhav L, Schweiger R, et al. Genome-wide methylation data mirror ancestry information. *Epigenetics Chromatin*. 2017;10:1. doi:10.1186/s13072-016-0108-y

56. Li S, Wong EM, Bui M, et al. Causal effect of smoking on DNA methylation in peripheral blood: a twin and family study. *Clin Epigenetics*. 2018;10:18. doi:10.1186/s13148-018-0452-9

57. Guintivano J, Aryee MJ, Kaminsky ZA. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. *Epigenetics*. Mar 2013;8(3):290-302. doi:10.4161/epi.23924

58. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics*. May 15 2014;30(10):1363-9. doi:10.1093/bioinformatics/btu049

59. Xu Z, Niu L, Li L, Taylor JA. ENmix: a novel background correction method for Illumina HumanMethylation450 BeadChip. *Nucleic Acids Res*. Feb 18 2016;44(3):e20. doi:10.1093/nar/gkv907

60. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. Apr 20 2015;43(7):e47. doi:10.1093/nar/gkv007

61. Viechtbauer W. Conducting Meta-Analyses inRwith themetaforPackage. *Journal of Statistical Software*. 2010;36(3)doi:10.18637/jss.v036.i03

62. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. Jan 1 2013;29(1):15-21. doi:10.1093/bioinformatics/bts635

63. Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics*. Oct 1 2016;32(19):3047-8. doi:10.1093/bioinformatics/btw354

64. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550. doi:10.1186/s13059-014-0550-8

65. Breen MS, Maihofer AX, Glatt SJ, et al. Gene networks specific for innate immunity define post-traumatic stress disorder. *Mol Psychiatry*. Dec 2015;20(12):1538-45. doi:10.1038/mp.2015.9

66. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics*. Aug 4 2011;12:323. doi:10.1186/1471-2105-12-323

67. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*. Jan 1 2010;26(1):139-40. doi:10.1093/bioinformatics/btp616

68. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol*. 2004;3:Article3. doi:10.2202/1544-6115.1027

69. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods*. Apr 2017;14(4):417-419. doi:10.1038/nmeth.4197

70. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. Aug 1 2014;30(15):2114-20. doi:10.1093/bioinformatics/btu170

71. Schneider VA, Graves-Lindsay T, Howe K, et al. Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. *Genome Res.* May 2017;27(5):849-864. doi:10.1101/gr.213611.116

72. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. *Bioinformatics*. Aug 15 2012;28(16):2184-5. doi:10.1093/bioinformatics/bts356

73. Nievergelt CM, Maihofer AX, Atkinson EG, et al. Discovery of 95 PTSD loci provides insight into genetic architecture and neurobiology of trauma and stress-related disorders. *medRxiv*. 2023:2023.08.31.23294915. doi:10.1101/2023.08.31.23294915